Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL.

Hemasphere · 2026 · PMC13274471 · PMID 42317203

Europe PMC DOI

hedged sentence

0.1126

closest p · 2.3× alpha

0.1126

boldest claim

The sentences

did not reach statistical significanceP = 0.1126not close (p > 0.1)

Importantly, while the additional effect over lusvertikimab monotherapy did not reach statistical significance (P = 0.1126), the dasatinib/lusvertikimab combination induced long‐term survival in the majority of tested PDX models, with 5 of 8 animals reaching the end of the 130‐day observation period.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.